CB 300919

HY-14375			
289715-28-2			
C ₃₂ H ₃₄ CIN ₇ O ₂			
584.11			
NAMPT			
Metabolic Enzyme/Protease			
Powder	-20°C	3 years	
	4°C	2 years	
In solvent	-80°C	2 years	
	-20°C	1 year	
	289715-28-2 C ₃₂ H ₃₄ ClN ₇ O 584.11 NAMPT Metabolic E Powder	289715-28-2 C ₃₂ H ₃₄ ClN ₇ O ₂ 584.11 NAMPT Metabolic Enzyme/Pr Powder -20°C 4°C In solvent -80°C	

SOLVENT & SOLUBILITY


In Vitro	DMSO : ≥ 100 mg/mL (171.20 mM) H ₂ O : < 0.1 mg/mL (insoluble) * "≥" means soluble, but saturation unknown.					
	Concentration Preparing 1 mM Stock Solutions 5 mM	Solvent Mass Concentration	1 mg	5 mg	10 mg	
		1 mM	1.7120 mL	8.5600 mL	17.1201 mL	
		5 mM	0.3424 mL	1.7120 mL	3.4240 mL	
		10 mM	0.1712 mL	0.8560 mL	1.7120 mL	
	Please refer to the so	lubility information to select the app	propriate solvent.			
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 3 mg/mL (5.14 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 3 mg/mL (5.14 mM); Suspended solution; Need ultrasonic					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 3 mg/mL (5.14 mM); Clear solution					

CTIV	ТТ
scription	CB 300919 is a quinazoline-based antitumour agent with high activity in the CH1 human ovarian tumour xenograft. CB 300919 has a continuous exposure (96 h) growth inhibition IC ₅₀ value of 2 nM in human CH1 ovarian tumor xenograft ^[1] .

REFERENCES

Product Data Sheet





[1]. Bavetsias, V. et al. The Design and Synthesis of Water-Soluble Analogues of CB30865, a Quinazolin-4-one-Based Antitumor Agent. Journal of Medicinal Chemistry (2002), 45(17), 3692-3702.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA